Glenmark Pharmaceuticals Ltd (Glenmark) manufactures, develops and markets branded and generic formulations, and OTC products. The company offers branded, generic, and over-the-counter (OTC) products. Glenmark specialises in major therapeutic areas such as respiratory, dermatology, and oncology. The company provides contract development and manufacturing operations services to various multinational and speciality pharmaceutical companies. It is also involved in the manufacture of active pharmaceutical ingredients (API). The company offers branded products like Ryaltris, Ascoril, and Alex in respiratory care, TEVIMBRA and Brukinsa in oncology, Telma in cardiology, Candid in dermatology, and LIRAFIT for diabetes. Its innovative products include Ryaltris, a fixed-dose nasal spray, and Winlevi, an anti-acne cream. The generics business primarily serves North America and Europe, with 215 generic products. The company distributes its products through a strong network of sales representatives and maintaining B2B and D2C connections. Glenmark also has a broad pipeline of innovative molecules in various stages of clinical development across oncology and immunology.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Glenmark's R&D is centered on differentiation, productivity, and commercial relevance. The company focuses on unmet patient needs, scientific feasibility, technical requirements, competitive landscape, and regulatory pathways. During FY2026, these priorities supported the approval and filing of respiratory products in the US, expansion of the injectables portfolio, international growth of Ryaltris, and the advancement of the oncology portfolio. The company aims to allocate scientific, financial, and organizational resources to opportunities where it can create a meaningful advantage. Glenmark has built expertise across respiratory, dermatology, and oncology, forming the foundation of its strategy to move up the value chain through differentiated product launches and an innovation-led portfolio. Glenmark has six global R&D centers located in Sinnar, Mahape, Neuchatel, New York, Taloja, and Lausanne. These centers are responsible for advancing complex generics, respiratory innovation, biosimilars, and next-generation biologics. The research ecosystem is designed to scale impactful science, accelerate differentiated therapies, and enable faster, more efficient global launches. As of March 2026, the company has over 1,360 granted patents. The company had 964 Employees in R&D activities. The company is developing innovative therapies, including bispecific and trispecific antibodies for multiple myeloma and solid tumours, as well as monoclonal antibodies for autoimmune diseases. In FY2026, the company spent INR10,000 million on its R&D activities, which as a percentage of revenue stood at 5.9%. As of March 2026, the company had 201 India and emerging markets filings, 1,500 inventions, 34 developed market filings, 10 out-licensed transactions, 9 active partnerships for innovative products and 220 generic products authorized for distribution in the US and 52 applications pending.